Die German Breast Group erforscht Brustkrebs und setzt dafür selbst entwickelte Studienkonzepte um.
Mit zusätzlichen wissenschaftlichen Forschungsprojekten wollen wir weitere Erkenntnisse über die Krankheit gewinnen.
Results of a next-generation sequencing (NGS) analysis conducted in the neoadjuvant GeparSepto study (GBG 69) have been published in the Clinical Cancer Research.
The initial results of AURORA were announced at the ESMO Breast Cancer Congress in Berlin.
Data of several GBG research projects will be presented at the ESMO Breast Cancer 2019, which takes place from 2 to 4 May in Berlin, Germany.
We are pleased to inform you that the results of the E-VITA study that evaluated the efficacy and tolerability of two schedules of eribulin and lapatinib in patients with trastuzumab-pretreated HER2-positive metastatic breast cancer has been published in the Anticancer Drugs.
A translational research study performed with samples obtained from a cohort of patients with HER2-negative breast cancer enrolled in the neoadjuvant GeparQuinto (GBG 44) trial has been published in the International Journey of Cancer.